Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250 Compliance
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt
Silver Dollar Samples Up to 2,753 g/t AgEq in Underground Sampling Campaign at its La Joya Silver Project
